Approval of Orladeyo in Japan for Prophylactic HAE Treatment
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for BioCryst Pharmaceuticals, Inc.’s oral, once-daily Orladeyo (berotralstat) 150 mg for prophylactic treatment of HAE in adults and pediatric patients 12 years and older. Orladeyo is the first and only prophylactic HAE medication approved in Japan. One capsule of [...]